We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Broadcom, Anthem and Allstate
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 20, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Boeing (BA - Free Report) , Broadcom (AVGO - Free Report) , Anthem and Allstate (ALL - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Johnson & Johnson, Boeing and Broadcom
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Boeing and Broadcom. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Johnson & Johnson’s shares have outperformed the Zacks Large-Cap Pharmaceuticals industry in the year-to-date period (1% vs. -1.5%). The Zacks analyst thinks that J&J is witnessing significant generic/biosimilar headwinds in the Pharma unit in 2019.
However, J&J’s sales and earnings growth is expected to accelerate in 2020 supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara. J&J is also making rapid progress with its pipeline and line extensions. It has already gained FDA approval for two new drugs in 2019, Balversa and Spravato.
Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. J&J’s shares have outperformed the industry this year. Headwinds like biosimilar/generic competition and pricing pressure remain. The talc and opioid lawsuits are overhangs on the stock.
Shares of Boeing have gained 2.7% in the past six months, underperforming the Zacks Aerospace & Defense industry’s rise of 16.2%. The Zacks analyst believes that the company’s proposed joint venture with Embraer will strengthen Boeing’s commercial business significantly.
Boeing remains the largest aircraft manufacturer globally in terms of revenues, orders and deliveries, and one of the major aerospace and defense contractors. Boeing expects the commercial fleet to be fueled by sustained annual growth in commercial passenger traffic along with a big wave of retiring, old planes.
However, the commercial business has suffered a major setback lately due to lower 737 deliveries, following the 737 Max product line's grounding and subsequent costs associated with it. Consequently, its revenues, earnings and cash flow position were affected significantly. This must have caused the company’s share price to underperform its industry year to date.
Broadcom’s shares have gained 3.1% in the past three months, underperforming the Zacks Electronics - Semiconductors industry’s rise of 5.8% over the same period. The Zacks analyst believes that the company is benefiting from strong demand for its wireless solutions and expanding product portfolio, which makes it well-positioned to address the needs of rapidly growing technologies like IoT and 5G.
The company intends to strengthen presence in the infrastructure software vertical particularly. In this regard, acquisition of CA and Symantec’s Enterprise Security Business remain extremely significant. Notably, shares of Broadcom have outperformed the industry in the past year.
Nonetheless, the company provided a tepid fiscal 2019 revenue view. Further, the company faces intensifying competition and integration risks due to frequent acquisitions. The company’s leveraged balance sheet continues to be a headwind.
Other noteworthy reports we are featuring today include Anthem and Allstate.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Broadcom, Anthem and Allstate
For Immediate Release
Chicago, IL – September 20, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Boeing (BA - Free Report) , Broadcom (AVGO - Free Report) , Anthem and Allstate (ALL - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Johnson & Johnson, Boeing and Broadcom
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Boeing and Broadcom. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Johnson & Johnson’s shares have outperformed the Zacks Large-Cap Pharmaceuticals industry in the year-to-date period (1% vs. -1.5%). The Zacks analyst thinks that J&J is witnessing significant generic/biosimilar headwinds in the Pharma unit in 2019.
However, J&J’s sales and earnings growth is expected to accelerate in 2020 supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara. J&J is also making rapid progress with its pipeline and line extensions. It has already gained FDA approval for two new drugs in 2019, Balversa and Spravato.
Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. J&J’s shares have outperformed the industry this year. Headwinds like biosimilar/generic competition and pricing pressure remain. The talc and opioid lawsuits are overhangs on the stock.
Shares of Boeing have gained 2.7% in the past six months, underperforming the Zacks Aerospace & Defense industry’s rise of 16.2%. The Zacks analyst believes that the company’s proposed joint venture with Embraer will strengthen Boeing’s commercial business significantly.
Boeing remains the largest aircraft manufacturer globally in terms of revenues, orders and deliveries, and one of the major aerospace and defense contractors. Boeing expects the commercial fleet to be fueled by sustained annual growth in commercial passenger traffic along with a big wave of retiring, old planes.
However, the commercial business has suffered a major setback lately due to lower 737 deliveries, following the 737 Max product line's grounding and subsequent costs associated with it. Consequently, its revenues, earnings and cash flow position were affected significantly. This must have caused the company’s share price to underperform its industry year to date.
Broadcom’s shares have gained 3.1% in the past three months, underperforming the Zacks Electronics - Semiconductors industry’s rise of 5.8% over the same period. The Zacks analyst believes that the company is benefiting from strong demand for its wireless solutions and expanding product portfolio, which makes it well-positioned to address the needs of rapidly growing technologies like IoT and 5G.
The company intends to strengthen presence in the infrastructure software vertical particularly. In this regard, acquisition of CA and Symantec’s Enterprise Security Business remain extremely significant. Notably, shares of Broadcom have outperformed the industry in the past year.
Nonetheless, the company provided a tepid fiscal 2019 revenue view. Further, the company faces intensifying competition and integration risks due to frequent acquisitions. The company’s leveraged balance sheet continues to be a headwind.
Other noteworthy reports we are featuring today include Anthem and Allstate.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.